Jeffrey Zonderman Joins RedShiftBio as its Chief Commercial Officer
Key Executive to Drive the Commercialization of Next Generation Biotechnology Instrumentation for Drug Discovery and Development
BURLINGTON, Mass.--(BUSINESS WIRE)--RedShift BioAnalytics, Inc., an innovative provider of bioanalytical instrumentation for the research, development and manufacturing of protein therapeutic drugs, recently announced the hiring of Jeffrey Zonderman as Chief Commercial Officer. Jeff brings over 25 years of experience in sales, marketing and business development within the life science and biotechnology markets. Using a great understanding of the workflow requirements and needs of the protein scientist, he has successfully launched automation, separations, and detection technology solutions into the biopharmaceutical market. Jeff brings to RedShift a strong focus on direct customer engagement and collaboration, and is ideally situated to realize the potential of RedShift’s powerful new bioanalytical tool that replaces five critical protein measurements in a single instrument while providing needed answers in half the time and at half the cost of current solutions.
RedShift recently announced the closing of a $11.0 million Series C Preferred Stock financing, co-led by Technology Venture Partners and Waters Corporation. RedShift’s platform provides customers a better measurement capability with an ease of use and lower cost per test than the alternative solutions in the market today. The Series C financing allows RedShift to accelerate the commercialization of its biotechnology instrument platform in 2017.
“It is impressive to see what the RedShift team has accomplished in both the development and market validation of their proprietary protein analysis technology and instrumentation,” said Jeff Zonderman. “I am incredibly excited to be joining RedShift to help drive forward its commercial success.”
“With the addition of Jeff to the RedShift team, we have taken another key step in building a world class organization to go along with our innovation bioanalytical platform,” commented Chip Marshall, CEO of RedShift. “Jeff has an incredible track record of success across many facets of the biopharma market and is a great addition to our team.”
About Technology Venture Partners (www.tvp.com)
Technology Venture Partners is a venture capital firm specializing in the technology and healthcare sectors. Technology Venture Partners principally invests in early to mid-stage venture opportunities that are centered on tangible product technologies, well defined market opportunities, and solid leadership teams at the inflection point of a company’s development.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT) develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.
About RedShift BioAnalytics, Inc. (www.redshiftbio.com)
RedShift BioAnalytics is a developer and manufacturer of bioanalytical tools for the life science market. The Company’s technology platform combines innovative lasers, microfluidics, and analytical technologies to achieve revolutionary improvement in measurement capability for the protein scientist and protein based drug therapies. Redshift is based in Burlington, Massachusetts.